Eir Ventures, a Nordic life science venture fund, has announced a first close of its new fund of EUR 76 million.

With a base in the Nordic region and a team of experienced life science investors, Eir Ventures will invest in innovative companies with products and technologies addressing significant unmet medical need and a potential to improve the life of patients, it states in its press release. The fund is launched with support from an investor syndicate comprising Saminvest, the European Investment Fund (EIF), Vækstfonden, Novo Holdings, as well as additional private investors.

“The Nordic region is ranked year after year as one of the most innovative areas in Europe, with a stable business environment and a successful track record of medical innovation and world-class science. However, the region is severely underserved with professional venture capital. Eir Ventures sees this as a unique opportunity that it will leverage,” says Stephan Christgau, Managing Partner of Eir Ventures.

Offices in Stockholm and Copenhagen

Eir Ventures has been set up by an experienced team of life science investors: Magnus Persson, Stephan Christgau, Andreas Segerros are the Managing Partners, and Amanda Hayward is Special Partner. It has offices in Stockholm and Copenhagen.

Eir Ventures will invest in high return potential opportunities in the Nordics, Europe and the US. The fund will have a particular focus on innovations from the leading universities and incubators in the Nordics and has established collaborations with select Nordic universities.

“In the current environment, where financing has become even more sparse and startups are struggling to fund development, healthcare innovation is more important than ever. We see great potential to bring some of the highly innovative treatments to patients with underserved medical needs, while also bringing outstanding returns to our investors,” says Magnus Persson, Managing Partner of Eir Ventures.

Image caption: Eir Venture’s management team: Stephan Christgau, Amanda Hayward, Andreas Segerros and Magnus Persson.